Phase II Study of Mitoguazone, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone for Patients with Diffuse Histologic Subtypes of Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Study (PE481)

References

• Pleshkewych A., Kramer D.L., Kelly E., et al. Independence of drug action on mitochondria and polyamines in L1210 leukemia cells treated with methylglyoxal bis (guanylhydrazone). Cancer Res 1980; 40: 4533–4540
   PubMed Web of Science ®Google Scholar
• Sartorelli A.C, Ianotti A.T., Booth B.A., Schneider F.H., Bertino J.R., Johns D.G. Complex formation with DNA and inhibition of nucleic acid synthesis by methylglyoxal bis (guanylhydrazone). Biochim Biophys Acta 1965; 103: 174–176
   PubMed Web of Science ®Google Scholar
• Knight IllW.A., Fabian C, Costanzi J.T., et al. Mrthylglyoxal bis-guanylhydrazone (methyl GAG, MGBG), in lymphoma and Hodgkin's disease. Invest New Drugs 1983; 1: 225–237
   PubMedGoogle Scholar
• Warrell R.P., Jr., Lee B.J., Kempin S.T., Lacher M.J., Straus D.J., Young C.W. Effectiveness of methyl-GAG (methylglyoxal-bis guanylhydrazone) in patients with advanced malignant lymphoma. Blood 1981; 57: 1011–1014
   PubMed Web of Science ®Google Scholar
• Levine A.M., Tulpule A., Tessman D., Kaplan L., Giles F., Luskey B.D., Scadden D.T., Northfelt D.W., Silverberg I., Wernz J., Espina B., Von Hoff D. Mitoguazone therapy in patients with refractory relapsed AIDS-related lymphoma: Results from a multicenter phase II trial. J Clin Oncol 1997; 15: 1094–1103
   PubMed Web of Science ®Google Scholar
• Cox D.R., Oakes D. The Analysis of Survival Data. Chapman and Hall, London 1984
   Google Scholar
• Gottlieb A.J., Anderson J.R., Ginsberg S.J., et al. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphoma. Cancer and Leukemia Group B study 7851. Cancer 1990; 66: 1888–1896
   PubMed Web of Science ®Google Scholar
• O'Connell M.J., Harrington D.P., Earle J.D., Johnson G.J., Click J.H., Carbone P.P., Creech R.H., Neiman R.S., Mann R.B., Silverstein M.N. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advnaced unfavorable histology non-Hodgkin's lymphoma. J Clin Oncol 1987; 5: 1329–1339
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Jr., Miller T.P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Montserrat E., García-Conde J., Viñolas N., López-Guillermo A., Hernández-Nieto L., Zubizarreta A., Maldonado J., Alcalá A., Faura M.V., Llorente A., Bladé J., Fontanillas M., Estapé J. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. Eur J Haematol 1996; 57: 377–383
   PubMed Web of Science ®Google Scholar
• J Linch D.C, Hudson B.V., Hancock B.W., Hoskin P.J., Cunningham D.C, Newland A.C., Milligan D.W., Stevenson P.A., Wood J.K., MacLennan K.A., Anderson L., Gregory W.M., Vaughn Hudson G. A randomised comparison of a third-generation regimen (PACE-BOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British national Lymphoma Investigation report. Br J Cancer 1996; 74: 318–322
   PubMed Web of Science ®Google Scholar
• Cooper I.A., Wolf M.M., Robertson T.I., Fox R.M., Matthews J.P., Stone J.M., Ding J.C., Dart G., Matthews J., Firkin F.C., Lowenthal R.M., Ironside P. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Martelli M., Storti S., Musso M., Canonetti M., Leone G., Cajozzo A., Papa G., Iannitto E., Perrotti A., Bendandi M., Gherlinzoni F., Gentilini P., Rossi G., Attini E., Mandelli F., Tura S. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 1995; 19: 329–335
   PubMed Web of Science ®Google Scholar
• Gordon L.I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G.D., Barcos M., Gottlieb A., O'Connell M. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Verdonck L.F., van Putten W.L.J., Hagenbeek A., Schouten H.C, Sonneveld P., van Imhoff G.W., Kluin-Nelemans H.C, Raemaekers J.M.M., van Oers R.H.J., Haak H.L., Schots R., Dekker A.W., de Gast G.C., Lowenberg B. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051
   PubMed Web of Science ®Google Scholar